Neuropathology of the Mcoln1(-/-) knockout mouse model of mucolipidosis type IV.
The recently developed Mcoln1(-/-) knockout mouse provides a novel model for analyzing mucolipin 1 function and mucolipidosis type IV disease. Here we characterize the neuropathology of Mcoln1(-/-) mouse at the end stage. Evidence of ganglioside accumulation, including increases in GM2, GM3, and GD3 and redistribution of GM1, was found throughout the central nervous system (CNS) independent of significant cholesterol accumulation. Unexpectedly, colocalization studies using immunofluorescence confocal microscopy revealed that GM1 and GM2 were present in separate vesicles within individual neurons. While GM2 was significantly colocalized with LAMP2, consistent with late-endosomal/lysosomal processing, some GM2-immunoreactivity occurred in LAMP2-negative sites, suggesting involvement of other vesicular systems. P62/Sequestosome 1 (P62/SQSTM1) inclusions were also identified in the CNS of the Mcoln1(-/-) mouse, suggesting deficiencies in protein degradation. Glial cell activation was increased in brain, and there was evidence of reduced myelination in cerebral and cerebellar white matter tracts. Autofluorescent material accumulated throughout the brains of the knockout mice. Finally, axonal spheroids were prevalent in white matter tracts and Purkinje cell axons. This neuropathological characterization of the Mcoln1(-/-) mouse provides an important step in understanding how mucolipin 1 loss of function affects the CNS and contributes to mucolipidosis type IV disease.
Micsenyi
Matthew C
MC
Dominick P. Purpura Department of Neuroscience, Rose F. Kennedy Center for Research in Mental Retardation and Human Development, Albert Einstein College of Medicine, Bronx, New York, USA.
Dobrenis
Kostantin
K
Stephney
Gloria
G
Pickel
James
J
Vanier
Marie T
MT
Slaugenhaupt
Susan A
SA
Walkley
Steven U
SU
D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism; D000818:Animals; D002490:Central Nervous System / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D004195:Disease Models, Animal; D005455:Fluorescent Antibody Technique; D005732:Gangliosides / Q000378:metabolism*; D005911:Gliosis / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D006360:Heat-Shock Proteins / Q000378:metabolism; D002479:Inclusion Bodies / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D052119:Lysosomal-Associated Membrane Protein 2 / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009081:Mucolipidoses / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology; D009413:Nerve Fibers, Myelinated / Q000378:metabolism / Q000473:pathology; D009474:Neurons / Q000378:metabolism / Q000473:pathology*; D000071456:Sequestosome-1 Protein; D013107:Sphingolipids / Q000378:metabolism; D050053:TRPM Cation Channels / Q000235:genetics*; D050051:Transient Receptor Potential Channels; D022161:Transport Vesicles / Q000378:metabolism / Q000473:pathology
D048868:Adaptor Proteins, Signal Transducing; D005732:Gangliosides; D006360:Heat-Shock Proteins; D052119:Lysosomal-Associated Membrane Protein 2; C512321:Mcoln1 protein, mouse; D000071456:Sequestosome-1 Protein; D013107:Sphingolipids; C101343:Sqstm1 protein, mouse; D050053:TRPM Cation Channels; D050051:Transient Receptor Potential Channels